Aldeyra Therapeutics, Inc. (ALDX) News
Filter ALDX News Items
ALDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALDX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ALDX News From Around the Web
Below are the latest news stories about ALDEYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate ALDX as an investment opportunity.
3 US Penny Stocks With Market Caps Over $80M To WatchAs the U.S. stock market concludes a strong year on a weak note, with major indices like the Dow experiencing significant monthly losses, investors are reflecting on opportunities within various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking potential growth despite their somewhat outdated label. By focusing on companies that exhibit solid financial health and promising prospects, investors can uncover potential value in... |
High Growth Tech Stocks To Watch In December 2024Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility. |
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately. |
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceLEXINGTON, Mass., December 02, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024. |
Top US Penny Stocks To Watch In November 2024As the U.S. stock market shows signs of a modest recovery, with major indices inching higher ahead of key earnings reports, investors are keenly observing smaller sectors for potential opportunities. Penny stocks, despite their somewhat outdated moniker, continue to attract attention as they often represent emerging companies that could offer growth at lower entry points. This article explores three penny stocks that stand out for their financial resilience and potential to provide compelling... |
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug ReproxalapThe FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises. |
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementLEXINGTON, Mass., November 18, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for |
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceLEXINGTON, Mass., November 14, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024. |
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?Here is how BellRing Brands (BRBR) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year. |
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingLEXINGTON, Mass., October 31, 2024--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024. |